( t) and GARDASIL was non-inferior whethe...)New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine,Health

t) and GARDASIL was non-inferior whether they were administered at the same visit or at a different visit. INDICATIONS AND USAGE GARDASIL is a vaccine indicated in girls and women 9-26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18: -- Cervical cancer -- Genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions: -- Cervical adenocarcinoma in situ (AIS) -- Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3 -- Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 -- Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 -- Cervical intraepithelial neoplasia (CIN) grade 1 CONTRAINDICATIONS Hypersensitivity to the active substances or to any of the excipients of the vaccine. Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of GARDASIL should not receive further doses of GARDASIL. PRECAUTIONS General As for any vaccine, vaccination with GARDASIL may not result in protection in all vaccine recipients. This vaccine is not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN. This vaccine will not protect against diseases that are not caused by HPV. GARDASIL has not been shown to protect against diseases due to non-vaccine HPV types. As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine. The decision to administer or delay vaccination because of a current or recent febrile illness depends largely on the severity of the symptoms and their etiology. Low-grade fever itself and mild upper respiratory infection are not generally contraindications to vaccination. Individuals with impaired immune responsiveness, whether due
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics